TY  - JOUR 
AU  - Dimopoulos, Meletios A.
AU  - García Sanz, Ramón
AU  - Gavriatopoulou, Maria
AU  - Morel, Pierre
AU  - Kyrtsonis, Marie-Christine
AU  - Michalis, Eurydiki
AU  - Kartasis, Zafiris
AU  - Leleu, Xavier
AU  - Palladini, Giovanni
AU  - Tedeschi, Alessandra
AU  - Gika, Dimitra
AU  - Merlini, Giampaolo
AU  - Kastritis, Efstathios
AU  - Sonneveld, Pieter
PY  - 2013
SN  - 0006-4971
UR  - http://hdl.handle.net/10366/155592
AB  - [EN]In this phase 2 multicenter trial, we evaluated the activity of bortezomib, dexamethasone, and rituximab (BDR) combination in previously untreated symptomatic patients with Waldenström macroglobulinemia (WM). To prevent immunoglobulin M (IgM)...
LA  - eng
PB  - American Society of Hematology
KW  - Waldenstrom Macroglobulinemia
KW  - Bortezomib
KW  - Dexamethasona
KW  - Rituximab
KW  - Therapy
KW  - Aged
KW  - Boronic Acids
KW  - Adult
KW  - Drug Administration Schedule
KW  - Humans
KW  - Pyrazines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
KW  - Waldenstrom Macroglobulinemia
KW  - Peripheral Nervous System Diseases
KW  - Immunoglobulin M
KW  - Antibodies
KW  - Treatment Outcome
KW  - Survival Analysis
KW  - Dexamethasone
TI  - Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
DO  - 10.1182/blood-2013-05-503862
T2  - Blood
VL  - 122
M2  - 3276
ER  -